Axogen, Inc. AXGN

Full chart Compare
Set alert

Price alert · AXGN

All alert types
49.50 USD 0.00 (+0.00%)

At closeNov 4, 2026, 8:43 AM EST

49.70 +0.20 +0.40%

Pre-market · Nov 4, 8:43 AM ET

49.18 Day range 50.84
23.00 52-week range 52.91
YTD
+51.24%
1 year
+108.25%
Market cap
2.96B
Revenue (ttm)
266.93M
Profit margin
-11.96%
EPS (ttm)
-0.63
Shares out
59.73M
Forward P/E
70.17
YTD return
+51.24%
1-year return
+108.25%
Volume
1.04M
Avg volume
1.39M
Open
50.49
Previous close
49.50
Day's range
49.18 – 50.84
52-week range
23.00 – 52.91
Beta
1.15
Analysts
Strong Buy
Price target
59.09 (+19.4%)
Earnings date
Feb 23, 2027

1m +0.07 (+0.14%)

5050.50Nov 350.40

Key statistics

Enterprise value
2.65B
PEG ratio
99.04
Price / sales
11.08
Price / book
5.96
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
26.20%
Free cash flow
29.81M
Total cash
348.07M
Total debt
19.47M
Return on equity
-10.35%
Short % of float
9.76%
50-day average
42.84
200-day average
39.66

Financials — quick view

All financials
AXGN Revenue — quarterly 75.83M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN Net income — quarterly 2.33M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN EPS — quarterly 0.04
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

AXGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.15———
Oct 28, 2026Sep 30, 20260.13130.21+0.08+59.94%
Jul 29, 2026Jun 30, 20260.12140.120.00-1.15%
Apr 28, 2026Mar 31, 20260.120.07-0.05-41.67%
Feb 24, 2026Dec 31, 20250.088790.07-0.02-21.16%
Oct 29, 2025Sep 30, 20250.090.12+0.03+33.33%

Upgrades / downgrades

AXGN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 29, 2026Leerink PartnersmainOutperformOutperform
Oct 29, 2026BarclaysmainOverweightOverweight
Oct 29, 2026Truist SecuritiesmainBuyBuy
Oct 29, 2026Wells FargomainOverweightOverweight
Oct 29, 2026HC Wainwright & Co.mainBuyBuy

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on AXGN — it syncs with the Stock Master app.

Insider holders

AXGN insider holders
InsiderRelationLatest transactionDateShares held
BEGAN MARC A.General CounselConversion of Exercise of derivative securityFeb 26, 202650,135
DALE MICHAEL DChief Executive OfficerSaleDec 9, 202563,537
DEVINNEY ERICK WAYNEOfficerSaleMar 15, 2026262,781
HARTLEY LINDSEY MARIEChief Financial OfficerSaleMay 6, 202665,146
KEMP JENS SCHROEDEROfficerSaleMay 6, 202672,451
LEVINE ALAN M.DirectorConversion of Exercise of derivative securityJun 17, 202650,893

Institution ownership

AXGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.40%4,419,208218.75MJun 29, 2026
Morgan Stanley4.60%2,747,924136.02MJun 29, 2026
First Light Asset Management, LLC4.60%2,748,361136.04MJun 29, 2026
Vanguard Capital Management LLC3.78%2,257,948111.77MJun 29, 2026
Artemis Investment Management Llp2.98%1,780,99288.16MSep 29, 2026
Polar Capital Holdings PLC2.51%1,500,82274.29MJun 29, 2026

Fund ownership

AXGN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,596,14979.01MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.31%1,380,75668.35MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund1.83%1,095,48254.23MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%609,72830.18MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.98%588,20029.12MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.96%576,28728.53MAug 30, 2026